Ascorbic acid 2-sulfate was shown to serve as a sulfating agent in vitro at elevated temperature or under mild oxidizing conditions (1, 2) . The in vivo sulfation of cholesterol by ascorbic acid 2-sulfate in the rat was recently reported (3, 4) . A single intracardial injection of [ 35 S]ascorbic acid 2-sulfate elevated the faecal excretion of cholesterol sulfate approximately fifty-fold. The hypocholesterolemic effect of ascorbic acid, as reported in man (5) as well as in laboratory animals (6, 7) , was postulated to be due to the intermediate synthesis of ascorbic acid 2-sulfate with subsequent transfer of the activated sulfate moiety onto cholesterol to form cholesterol sulfate which is then flushed out of the body (4) . Ascorbic acid 2-sulfate was identified äs a significant metabolite of ascorbic acid in animals and man (8) (9) (10) and it has been suggested that it acts as a long-term storage form in the ascorbic acid pool of the body (11) . This report deals with the effect of ascorbic acid 2-sulfate, given over a period of 5 days by daily intravenous injection, on the faecal excretion of radioactivity after a single intravenous administration of [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]cholesterol in rats. The aim of this study was to examine whether the administration of ascorbic acid 2-sulfate enhances the faecal or urinary excretion of radioactive material, especially of cholesterol sulfate, and whether the accumulation of exogenous cholesterol by various tissues is decreased.
Materials and Methods
Chemicals: [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] CJcholesterol (55.6 mCi/mmple), dissolved in benzene, was purchased from The Radiochemical Centre, Amersham. Ascorbic acid 2-sulfate (dipotassium salt), sodium ascorbate and cholesterol sulfate (ammonium salt) were supplied by Hoffmann-La Roche, Atlas G-1290 by Atlas" Chemie (Essen, Germany). All other chemicals were of reagent grade and from commercial sources. * Animals: Female rats (strain Füllinsdorf Albino) were maintained on a commercial diet (Nafag 199, by Nafag, Gossau, Switzerland). They were divided into 3 groups (SD given): controls (167.1 ± 9.4 g of weight) and two ex-" perimental groups receiving 10 mg ascorbic acid 2-sulfate daily (165.7 ± 16.2 g) or 20 mg ascorbic acid 2-sulfate daily (165.2 ± 15.0 g). Ascorbic acid 2-sulfate was dissolved in 0.15 mol/1 sodium phosphate buffer, pH 7.4, to a final concentration of 10 or 20 mg/500 . The solutions were injected daily for 5 days via the tau vein. The control animals were injected with only the buffer (500 ). 7 animals were taken for each experiment. Additional controls (2 animals) received a solution of sodium ascorbate (33 mg/500 buffer) or a solution of K 2 SO 4 (Merck, 10 mg/500 buffer). A single dose of 22.8 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]cholesterol (159 g) was administered via the same route in an emulsified form (300 ) 5 h after the last injection of ascorbic acid sulfate, sodium ascorbate or K 2 SO 4 . This emulsion was prepared as follows: the benzene was evaporated from the cholesterol solution and the residue was emulsified in isotonic NaQ after addition of a small volume of emulgator Atlas O1290 and propylene glycol. The animals were kept for 72 h.in metabolic cages for the collection of faeces and urine, they had free access to the diet. After decapitation, the abdomen was opened and the liver, spleen, kidneys and adrenal glands were removed and processed for counting of radioactivity Counting of the radioactive material: The faeces were homogenized with a 4-fold amount of water (Polytron, Kinematica, Lucerne, Switzerland) and incubated for 10 min at 60° C. The radioactive material was extracted from the homogenate at room temperature several times with chloroform/methanol, 10 ml + 10 ml (15-fold volume). After centrifugation, the supernatants were brought to a constant volume (250 ml). Aliquot s were counted for radioactivity and were used for Chromatographie identification of the labelled material. The urine was directly counted for radioactivity (100 μΐ). Solubilization of the tissues (approx. 50 mg) was achieved with Soluene-100 solubilizer (Packard) as described in detail elsewhere (12) . The radioactivity was determined using a Nuclear Chicago Unilux II liquid scintillation spectrometer equipped with an Olivetti Programma 101 computerized for direct calculation of disintegrations per min (dpm). The external standard method for quenche correction was employed. A mixture of ethanol and scintillator solution (8 g Butyl-PBD [CIBAJ/1 toluene), 4:15, volumes, was used for counting.
Chromatography: The extracts from the faeces were chromatographed on thin-layer plates (silica gel Ρ 254 , Merck). Solvent systems were as follows: (I) benzene/ethanol/methylethylketone/water, 30 ml + 30 ml + 30 ml + 10 ml· (13) and (II) ethylacetate/pyridine/acetic acid/water, 62 ml + 21 ml + 6 ml + 1 ml (14) . As standards, cholesterol, cholesterol sulfate and sodium taurocholate were used. For the quantitative determination of the composititon of the radioactive material in the faeces, system II was employed. The 3 labelled fractions were eluted with chloroform/methanol (10 ml + 50 ml, unpolar zone, cholesterol and triglycerides) or with chloroform/methanol (20 ml + 10 ml, cholesterol sulfate-containing zone) or with chloroform (polar zone, sodium taurocholate). The solvents were evaporated and the amounts of radioactivity were determined in the residues. Student's t-test was used for statistical evaluation of the data (15).
Results
In Table 1 , the values for the total faecal as well as urinary excretion of 14 C-radioactivity are given. A significant reduction in the faecal excretion of radioactive material was seen in the first 72 h after the administration of [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]cholesterol to rats which had been treated for a period of 5 days with daily injection of 10 mg or 20 mg ascorbic acid 2-sulfate (27.2% or 28.3% of the labelled dose); the controls received an injection of buffer only (33.9%) (p < 0.02 and p < 0.01, respectively), or a solution containing 10 mg K 2 SO 4 (32.6%). However, sodium ascorbate (33 mg) had a similar effect to ascorbic acid 2-sulfate, with regard to the excretion of radioactivity in the faeces (25.8% of the administered dose). The urinary excretion of 14 C-radioactivity was found to be enhanced following the injection of 10 mg or 20 mg ascorbic acid 2-sulfate (2.2% or 2.5% of the dose; treatment with buffer, 1.6%). The application of sodium ascorbate (33 mg), or K 2 SO 4 (10 mg) caused an even higher excretion (3.7% and 3.9%, respectively). Table 2 summarizes the quantitative composition of the labelled material in the faeces. Cholesterol and triglycerides (unpolar zone) accounted for nine-tenths of the radioactivity, whereas only approx. 6% were found as cholesterol sulfate. The polar fraction contained 3-4% of the label. No stimulatory effect on the excretion of either cholesterol or cholesterol sulfate could be observed by ascorbic acid 2-sulfate as compared with the controls (buffer, sodium ascorbate or K 2 SO 4 ). The total radioactivity remaining in the liver, spleen, kidneys and adrenals 72 h after the single injection of [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]cholesterol is given in Table 3 . The accumulation of label was higher in the organs of rats injected with ascorbic acid 2-sulfate. No significant difference existed either in the liver, spleen, or in the kidneys of rats in the ascorbic acid 2-sulfate treated group. However, a significant increase in the accumulation of radioactivity was found in the adrenal glands after treating rats with 20 mg ascorbic acid 2-sulfate (p < 0.02), but the total radioactivity did not reach the amounts observed after dosage of either sodium ascorbate or K 2 SO 4 . The weights of the organs per 100 g of body weight were not influenced by the treatment with ascorbic acid 2-sulfate. C]cholesterol (159 Mg) to female rats which had been treated for 5 days with a daily injection of ascorbic acid 2-sulfate dipotassium salt (10 or 20 mg, n = 7) in 0.15 mol/1 sodium phosphate buffer (pH 7.4) or with buffer. For additional controls, 2 animals were injected either with 33 mg sodium ascorbate in buffer or with 10 mg K 2 SO 4 in buffer'. The faeces were extracted as described in the experimental part; the urine (100 μΐ) was directly counted for radioactivity. 
Compound

Discussion
The effect of intravenously administered ascorbic acid 2-sulfate, given over a period of 5 days, on the excretion of a single exogenous dose of [ 14 C]cholesterol was studied in normal female rats. No stimulatory effect of this ascorbic acid derivative on the excretion of either free cholesterol or cholesterol sulfate could be observed. On the contrary, treatment with either sodium ascorbate (33 mg) or ascorbic acid 2-sulfate (10 mg or 20 mg) caused a significant reduction of the total radioactivity excreted in the faeces (Table 1) in comparison with the results obtained after treatment with buffer or with K 2 SO 4 (10 mg). However, the composition of the excreted radioactive material was unaffected (approx. 90% cholesterol and 6% cholesterol sulfate) ( Table 2 ). The fact that the excretion of labelled material can be reduced by treatment with sodium ascorbate is surprising, since the rat is able to produce ascorbic acid biosynthetically (16) . Since ascorbic acid sulfate treatment evoked a similar effect, the question arises whether sodium ascorbate can be converted enzymatically into ascorbic acid 2-sulfate which then could be considered as the active compound. Several reports have appeared indicating an in vivo sulfatation of ascorbic acid into ascorbic acid 2-sulfate. After the oral administration of labelled ascorbic acid, ascorbic acid sulfate was shown to be excreted in the bile (9, 17) . Since ascorbic acid 2-sulfate has been suggested to be part of the ascorbic acid body pool as a long-term storage form (8) , one might even assume that ascorbic acid 2-sulfate can only evoke this decrease in faecal ex- cretion after administration of cholesterol as long as this derivative of ascorbic acid is not integrated in the ascorbic acid body pool. Our results are in accordance with the observation that the sulfate moiety of ascorbic acid 2-sulfate can be transferred in vivo onto cholesterol to form cholesterol sulfate (3, 4) . However, the enhancement of the faecal excretion of cholesterol sulfate by ascorbic acid 2-sulfate could not be confirmed (Table 2 ). This was postulated from observations following the intracardial injection of a single dose of ascorbic acid 2-[ 35 S]sulfate into rats. This would mean that the effect of ascorbic acid 2-sulfate on the endogenous cholesterol was investigated, whereas in our study the effect of ascorbic acid 2-sulfate was studied on exogenously administered cholesterol. However, in studies with rats in which the cholesterol pool was gradually labelled by the intravenous application of [ 14 C]mevalonate prior to intraperitoneal treatment with ascorbic acid 2-sulfate, there was still no stimulatory effect on the cholesterol metabolism with regard to an enhanced excretion of 14 C-labelled material in the faeces 2 ). From our studies it is to be concluded that the hypo-* cholesterolemic effect of ascorbic acid is not attributable to ascorbic acid 2-sulfate. In the adrenal glands the amount of 14 C-radioactivity was found to be about twice as much in sodium ascorbate-treated rats as compared with rats pretreated with ascorbic acid 2-sulfate. On the other hand, the administration of ascorbic acid enhanced the concentration of labelled material derived from [ 14 C]cholesterol in the adrenals significantly (Table 3 ). This observation might possibly be related to an increased hydroxylatiqn of cholesterol at position C-7 by ascorbic acid 2-sulfate. In guinea pig liver homogenates cholesterol is mainly converted to 7a-hydroxycholest-4-en-3-one (18) . Recently, a control function was suggested for ascorbic acid in the transformation of cholesterol to bile acids (19) . Thus, it would be of interest to study the possible effect of ascorbic acid 2-sulfate in this transformation reaction.
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